查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602818

抗凝血逆轉藥物市場：依產品、分佈 - 全球預測 2025-2030

Anticoagulant Reversal Drugs Market by Product (Andexxa, Idarucizumab, Protamine), Distribution (Hospital Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗凝血逆轉藥物市值為6.4638億美元，預計2024年將達7.254億美元，複合年成長率為12.31%，預計2030年將達到14.5759億美元。

抗凝血逆轉劑是重要的藥物，用於在藥物過量、緊急外科手術和失控出血等情況下抵消抗凝血劑的作用。這些藥物在醫療實踐中發揮重要作用，為接受抗凝血治療的患者提供安全網並使凝血恢復正常。主要用途範圍從醫院急診醫學到循環系統和血液學等特定醫療部門。最終用戶主要是醫院、診所和門診手術中心。抗凝血逆轉藥物市場的成長是由心血管疾病盛行率上升、抗凝血治療接受度提高、外科手術數量增加以及醫療保健安全網意識和投資不斷成長等因素推動的。最新的商機在於開發更快、更有效的抗逆流藥物，鑑於醫療緊急情況的快速發展，這可以提供競爭優勢。與提高這些藥物的療效和安全性相關的研究投資也至關重要，特別是透過精準醫療為個別患者需求量身訂做解決方案。然而，市場面臨重大挑戰，包括高昂的藥物開發成本、嚴格的監管監督以及逆轉藥物可能導致併發症的潛在副作用。此外，新興市場的知名度和准入有限也可能阻礙市場擴張。市場競爭非常激烈，領先的公司都專注於研發，以提供創新的解決方案並擴大產品系列。一些最好的創新領域包括開發長效逆轉藥物、最大限度地減少副作用以及探索將人工智慧整合到個人化治療計劃的預測分析中。市場的動態本質要求相關人員能夠適應技術進步和監管變化。市場參與企業應注重策略夥伴關係和聯盟，以豐富其產品種類，開拓開拓的市場，並確保永續的長期成長。

主要市場統計
基準年[2023] 64638萬美元
預測年份 [2024] 7.254 億美元
預測年份 [2030] 1,457.59 百萬美元
複合年成長率（%） 12.31%

市場動態：快速發展的抗凝血逆轉藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗凝血逆轉藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 出血性疾病和抗凝血治療的盛行率增加
    • 全球產品核可增加
    • 計劃外手術增加
  • 市場限制因素
    • 專利藥高成本
  • 市場機會
    • 完善全球報銷政策
    • 繼續進行研究工作並提供資金來治療抗凝血相關出血
  • 市場挑戰
    • 由於重新啟動抗凝血治療存在嚴重風險，需要進行嚴格的監管改革

波特五力：駕馭抗凝血逆轉市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗凝血逆轉藥物市場的外部影響

外部宏觀環境因素在塑造抗凝血逆轉藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗凝血逆轉藥物市場競爭狀況

抗凝血逆轉藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣抗凝血逆轉藥物市場供應商績效評估

FPNV定位矩陣是評估抗凝血逆轉藥物市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪抗凝血逆轉藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，抗凝血逆轉藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 出血性疾病和抗凝血治療的盛行率增加
      • 全球產品核可數量增加
      • 計劃外手術增加
    • 抑制因素
      • 專利藥高成本
    • 機會
      • 完善全球報銷政策
      • 抗凝血相關出血治療的持續研究與資助
    • 任務
      • 與抗凝血逆轉相關的重大風險需要嚴格的監管改革
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章抗凝血逆轉藥物市場：依產品

  • 安德克薩
  • 伊達賽珠單抗
  • 魚精蛋白
  • 氨甲環酸
  • 維生素K

第7章 抗凝血逆轉藥物市場經銷商

  • 醫院藥房
  • 零售藥房

第8章美洲抗凝血逆轉藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太抗凝血逆轉藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲抗凝血逆轉藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alexion Pharmaceuticals Inc.
  • AMAG Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies, Inc.
  • BioVascular Inc.
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Limited
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Dr Reddy's Laboratories Ltd,
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Genentech, Inc.
  • Hikma Pharmaceuticals PLC
  • Octapharma AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
Product Code: MRR-035DA3C636BB

The Anticoagulant Reversal Drugs Market was valued at USD 646.38 million in 2023, expected to reach USD 725.40 million in 2024, and is projected to grow at a CAGR of 12.31%, to USD 1,457.59 million by 2030.

Anticoagulant reversal drugs are crucial medications used to counteract the effects of anticoagulants in situations such as overdosage, urgent surgical procedures, or uncontrolled bleeding. These drugs serve an essential role in medical settings, providing a safety net for patients undergoing anticoagulant therapy by quickly restoring normal blood clotting. The main applications span from emergency care in hospitals to specific medical departments like cardiology and hematology. End-users primarily include hospitals, clinics, and ambulatory surgical centers. Market growth for anticoagulant reversal drugs is driven by factors such as the rising incidence of cardiovascular diseases, increasing acceptance of anticoagulation therapy, a growing number of surgical procedures, and heightened awareness and investment in healthcare safety nets. Latest opportunities lie in developing more rapid and effective reversal agents, which could provide competitive advantages given the fast-paced nature of medical emergencies. Investment in research related to improving the efficacy and safety profile of these drugs is also crucial, particularly in customizing solutions for individual patient needs through precision medicine. However, the market faces significant challenges, including high drug development costs, stringent regulatory scrutiny, and potential side effects of reversal agents that can lead to complications. Additionally, limited awareness and access in developing regions may hinder market expansion. The market is highly competitive, with major players focusing on R&D to offer innovative solutions and expand their product portfolios. The best innovation areas include developing longer-acting reversal agents, minimizing adverse effects, and exploring the integration of AI in predictive analytics for personalized treatment plans. The nature of the market is dynamic and demands adaptability from stakeholders to stay abreast of technological advancements and regulatory changes. Market participants should focus on strategic partnerships and collaborations to enhance product offerings and tap into untapped markets, ensuring sustainable and long-term growth.

KEY MARKET STATISTICS
Base Year [2023] USD 646.38 million
Estimated Year [2024] USD 725.40 million
Forecast Year [2030] USD 1,457.59 million
CAGR (%) 12.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticoagulant Reversal Drugs Market

The Anticoagulant Reversal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of bleeding disorders and anticoagulant therapies
    • Growing number of product approvals worldwide
    • Increasing incidence of unplanned surgeries
  • Market Restraints
    • High cost of the patent drugs
  • Market Opportunities
    • Improvements in reimbursement policies globally
    • Ongoing research activities and funding to treat anticoagulant-related bleeds
  • Market Challenges
    • Stringent regulatory reforms due to severe risks associated with the reversal of anticoagulation

Porter's Five Forces: A Strategic Tool for Navigating the Anticoagulant Reversal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticoagulant Reversal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticoagulant Reversal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticoagulant Reversal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticoagulant Reversal Drugs Market

A detailed market share analysis in the Anticoagulant Reversal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticoagulant Reversal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticoagulant Reversal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticoagulant Reversal Drugs Market

A strategic analysis of the Anticoagulant Reversal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulant Reversal Drugs Market, highlighting leading vendors and their innovative profiles. These include Alexion Pharmaceuticals Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., AstraZeneca PLC, Bausch Health Companies, Inc., BioVascular Inc., Boehringer Ingelheim GmbH, Cadila Healthcare Limited, CSL Limited, Daiichi Sankyo Company, Limited, Dr Reddy's Laboratories Ltd,, Eli Lilly and Company, Fresenius Kabi AG, Genentech, Inc., Hikma Pharmaceuticals PLC, Octapharma AG, Otsuka Pharmaceutical Co., Ltd., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulant Reversal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Andexxa, Idarucizumab, Protamine, Tranexamic Acid, and Vitamin K.
  • Based on Distribution, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bleeding disorders and anticoagulant therapies
      • 5.1.1.2. Growing number of product approvals worldwide
      • 5.1.1.3. Increasing incidence of unplanned surgeries
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the patent drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in reimbursement policies globally
      • 5.1.3.2. Ongoing research activities and funding to treat anticoagulant-related bleeds
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory reforms due to severe risks associated with the reversal of anticoagulation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anticoagulant Reversal Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Andexxa
  • 6.3. Idarucizumab
  • 6.4. Protamine
  • 6.5. Tranexamic Acid
  • 6.6. Vitamin K

7. Anticoagulant Reversal Drugs Market, by Distribution

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies

8. Americas Anticoagulant Reversal Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anticoagulant Reversal Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anticoagulant Reversal Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alexion Pharmaceuticals Inc.
  • 2. AMAG Pharmaceuticals, Inc.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. AstraZeneca PLC
  • 5. Bausch Health Companies, Inc.
  • 6. BioVascular Inc.
  • 7. Boehringer Ingelheim GmbH
  • 8. Cadila Healthcare Limited
  • 9. CSL Limited
  • 10. Daiichi Sankyo Company, Limited
  • 11. Dr Reddy's Laboratories Ltd,
  • 12. Eli Lilly and Company
  • 13. Fresenius Kabi AG
  • 14. Genentech, Inc.
  • 15. Hikma Pharmaceuticals PLC
  • 16. Octapharma AG
  • 17. Otsuka Pharmaceutical Co., Ltd.
  • 18. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. ANTICOAGULANT REVERSAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTICOAGULANT REVERSAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTICOAGULANT REVERSAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTICOAGULANT REVERSAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICOAGULANT REVERSAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY ANDEXXA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY IDARUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PROTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY TRANEXAMIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY VITAMIN K, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM ANTICOAGULANT REVERSAL DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. ANTICOAGULANT REVERSAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ANTICOAGULANT REVERSAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023